DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 16:59:36 31/05/2024 BST | ||
| 0.88 EUR | +2.33% |
|
| 1 month | +3.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.88 | +2.33% |
| 30/05/24 | 0.86 | -1.15% |
| 29/05/24 | 0.87 | -2.25% |
| 28/05/24 | 0.89 | +1.14% |
| 27/05/24 | 0.88 | -6.38% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 04:59 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7F |
| ISIN | DE000MG0D7F7 |
| Date issued | 18/03/2024 |
| Strike | 325 $ |
| Maturity | 21/03/2025 (292 Days) |
| Parity | 10 : 1 |
| Emission price | 0.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.36 € |
|---|---|
| Lowest since issue | 0.62 € |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
236.2
USD
Average target price
363.9
USD
Spread / Average Target
+54.07%
- Stock Market
- Certificates
- Certificat
